← Leaderboards
Yong Wu
Charles R. Drew University Of Med & Sci
$3,543,249
Attributed
$3,543,249
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $366.2K · FY2015–25$500K$375K$250K$125K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,543,249 · 3
By mechanism
SC1$2,870,000 · 2
U54$673,249 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Health Disparity”
- Chanza Baytop · Westat, Inc.$271,217,917
- Sid E O'Bryant · University Of North Texas Hlth Sci Ctr$110,543,679
- Rebecca Montalvan · Westat, Inc.$86,600,000
- Valerie C. Montgomery-Rice · Meharry Medical College$85,077,900
- Robert P Kimberly · University Of Alabama At Birmingham$77,343,402
- Judith Kasper · Johns Hopkins University$74,869,189
Research focus
Health DisparityCellsMalignant Breast NeoplasmMalignant NeoplasmsAffectCell ProliferationBreast Cancer PatientGlucoseWomanComplexHyperglycemiaLatinaNeoplastic CellDiabetic MouseAfrican AmericanLightDiabeticIn VivoDiabetes MellitusSignal TransductionAnimalsAnimal ModelDrug TargetingDose
Grant awards (10)
Development and Therapeutic Efficacy of a Novel Lactate Transporter inhibitor (MCT4) CB-202 in tumors that overexpress MCT4, such as Triple-Negative Breast Cancer (TNBC) and Acute Myeloid Leukemia (AL$307,087
U54 · FY2025 · MD · contact PI
Development and Therapeutic Efficacy of a Novel Lactate Transporter inhibitor (MCT4) CB-202 in tumors that overexpress MCT4, such as Triple-Negative Breast Cancer (TNBC) and Acute Myeloid Leukemia (AL$366,162
U54 · FY2024 · MD · contact PI
A novel metabolic reprograming strategy for the treatment of diabetes-associated breast cancer$358,750
SC1 · FY2023 · GM · contact PI
A novel metabolic reprograming strategy for the treatment of diabetes-associated breast cancer$358,750
SC1 · FY2022 · GM · contact PI
A novel metabolic reprograming strategy for the treatment of diabetes-associated breast cancer$358,750
SC1 · FY2021 · GM · contact PI
A novel metabolic reprograming strategy for the treatment of diabetes-associated breast cancer$358,750
SC1 · FY2020 · GM · contact PI
Mechanisms behind hyperglycemia-associated breast cancer risk and progression$358,750
SC1 · FY2018 · CA · contact PI
Mechanisms behind hyperglycemia-associated breast cancer risk and progression$358,750
SC1 · FY2017 · CA · contact PI
Mechanisms behind hyperglycemia-associated breast cancer risk and progression$358,750
SC1 · FY2016 · CA · contact PI
Mechanisms behind hyperglycemia-associated breast cancer risk and progression$358,750
SC1 · FY2015 · CA · contact PI